Home|About This Site|About Us|Maps & Parking|Giving|Contact Us|Careers|Med-U-Nurse
Medical University Hospital home page
Center for Drugs and Alcohol Programs
Search:

Center for Drug & Alcohol Programs

About CDAP
Faculty

Clinical Services
Basic Science Research
Clinical Trials
Research
Seminars
Recent Publications
Highlighted Events
Grand Rounds
Journal Clubs
Training
Job Opportunities
Conferences
Addiction Information
Podcast Library
Video Library
Giving
Contact Us
For Faculty & Staff
Quick Links


Patients and Visitors
Medical Services
Health Information
Community Events
Health Professionals
Home > CDAP > Dr. Raymond Anton
Dr. Raymond Anton

email icon

printer icon

print

Distinguished University Professor   
Professor, Department of Psychiatry and Behavioral Sciences
Director, Center for Drug & Alcohol Programs
Director, Clinical Neurobiology Laboratory

EDUCATION

Rutgers College, New Brunswick, NJ    B.A.     1972     Biosciences
Rutgers School of Medicine, New Brunswick, NJ    M.D.1976Medicine
Greenwich Hospital, Greenwich, CTInternship  1977Medicine
Yale New Haven Hospital & Connecticut Mental Health Center, New Haven, CTResidency1980Psychiatry
Yale University School of Medicine, New Haven, CTPostdoctoral   1980Psychiatry

PROFESSIONAL EXPERIENCE

1980-1985Assistant Professor, Department of Psychiatry & Behavioral Sciences, MUSC, Charleston, SC
1980-1988Staff Psychiatrist, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC
1984-1988Director, Psychopharmacology Research, Veterans Affairs Medical Center, Charleston, SC
1985-1991Associate Professor, Department of Psychiatry & Behavioral Sciences, MUSC, Charleston, SC
1988-presentDirector, Clinical-Neurobiology Laboratories, Department of Psychiatry & Behavioral Sciences, MUSC, Charleston, SC
1991-presentProfessor, Department of Psychiatry & Behavioral Sciences, MUSC, Charleston, SC
1993-2001Director, Alcohol Medication Studies, Center for Drug and Alcohol Programs, MUSC, Charleston, SC
1995-presentScientific Director for Clinical Research, Charleston Alcohol Research Center, MUSC, Charleston, SC
2001-presentDirector, Center for Drug and Alcohol Programs, MUSC, Charleston, SC
2002-presentDistinguished University Professor, MUSC, Charleston, SC

AWARDS AND HONORS

1991NIAAA Alcohol Psychosocial Research Review Committee (Member Clinical & Treatment Subcommittee; Chair, 1993-1994)
1992NIAAA Working Group on Methodology in Clinical Treatment Research Trials
1992NIAAA Task Force on Revision of the Treatment Assessment Manual
1996American College of Neuropsychopharmacology (elected member)
1997American Society of Addiction Medicine (diplomat)
1997Added Qualifications in Addiction Psychiatry
1999Board of Directors, Research Society on Alcoholism
1999-2002Board of Scientific Counselors of the National Institute of Alcohol Abuse and Alcoholism
2000-presentMember, Board of reviewing Editors, Alcoholism: Clinical and Experimental Research
2000-presentChairman, Steering Committee, COMBINE Study
2001Treasurer, Research Society on Alcoholism
2003American College of Neuropsychopharmacology (elected fellow)
2005Vice-Chairman, Board of Trustees, Alcohol Beverage Medical Research Foundation
2007-2008President, Research Society on Alcoholism
2008Distinguished Fellow, American Psychiatric Association


RECENT PUBLICATIONS

Anton RF. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics 9(6):655-658, 2008.

Anton RF. Naltrexone for the management of alcohol dependence. New England Journal of Medicine 359(7):715-721, 2008. NIHMSID: NIHMS67847, PMCID: PMC2565602

Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH & Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. Journal of Clinical Psychopharmacology 28(1):5-12, 2008.

Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H & Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry 65(2):135-144, 2008.

Baros AM, Latham PK & Anton RF. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: Do sex differences exist? Alcoholism: Clinical & Experimental Research 32(5):771-776, 2008. NIHMSID: NIHMS65293, PMCID: PMC2553698

Baros AM, Wright TM, Latham PK, Miller PM & Anton RF. Alcohol consumption, %CDT, GGT and blood pressure change during alcohol treatment. Alcohol & Alcoholism 43(2):192-197, 2008.

Covault J, Gelernter J, Jensen K, Anton R & Kranzler HR. Markers in the 5'-region of GABRG1 associate to alcohol dependence and are in linkage disequilibrium with markers in the adjacent GABRA2 gene. Neuropsychopharmacology 33(4):837-848, 2008.

Donovan DM, Anton RF, Miller WR, Longabaugh R, Hosking JD, Youngblood M & Combine Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): Examination of posttreatment drinking outcomes. Journal of Studies on Alcohol 69(1):5-13, 2008.

Jeppsson JO, Arndt T, Schellenberg F, Wielders JP, Anton RF, Whitfield JB & Helander A. Standardization of carbohydrate-deficient transferrin: Reply to the letter by Tagliaro and Bortolotti. Clinical Chemistry and Laboratory Medicine 46(5):727-728, 2008.

Johnson BA, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS & Swift RM. Topiramate as treatment for alcohol dependence-Reply. Journal of the American Medical Association 299(4):406-407, 2008.

Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Addolorato G, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM, Topiramate for Alcoholism Advisory Board & Topiramate for Alcoholism Study Group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Archives of Internal Medicine 168(11):1188-1199, 2008.

Luo X, Zuo L, Kranzler HR, Wang S, Anton RF & Gelernter J. Recessive genetic mode of an ADH4 variant in substance dependence in African-Americans: A model of utility of the HWD test. Behavioral and Brain Functions 4:42, 2008. PMCID: PMC2563013

Myrick H, Anton RF, Li X, Henderson S, Randall PK & Voronin K. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Archives of General Psychiatry 65(4):466-475, 2008. NIHMSID: NIHMS55593, PMCID: PMC2504413

Stewart SH, Latham PK, Miller PM, Randall P & Anton RF. Blood pressure reduction during treatment for alcohol dependence: Results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction 103(10):1622-1628, 2008. NIHMSID: NIHMS85866.

Voronin K, Randall P, Myrick H & Anton R. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm - Possible influence of self-control. Alcoholism: Clinical & Experimental Research 32(11):1954-1961, 2008. NIHMSID: NIHMS64368, PMCID: PMC2588475

Farrer, L.A., Kranzler, H.R., Yu, Y., Weiss, R.D., Brady, K.T., Anton, R., Cubells, J.F., Gelernter, J. Association of variants in MANEA with cocaine-related behaviors. Archives of General Psychiatry 66(3):267-274, 2009.

Stewart SH, Oroszi G, Randall PK & Anton RF. COMT genotype influences the effect of alcohol on blood pressure: Results from the COMBINE study. American Journal of Hypertension 22(1):87-91, 2009. NIHMSID: NIHMS85665

Page last updated: 03/06/2009
privacy statements | 

disclaimer

 | accessibility |  press room |  find a doctor | site map | e-newsletters
© 2009 Medical University of South Carolina
Health on the Net Foundation sealWe subscribe to the
HONcode Principles
Verify Here